Immune therapies in multiple myeloma

SK Kumar, KC Anderson - Clinical Cancer Research, 2016 - AACR
Abstract Treatment paradigms have changed rapidly for multiple myeloma, and immune
therapies have taken center stage. Advances in therapies for myeloma have led to a …

Current development of monoclonal antibodies in cancer therapy

S Parakh, D King, HK Gan, AM Scott - … Immunotherapeutic Strategies in …, 2020 - Springer
Exploiting the unique specificity of monoclonal antibodies has revolutionized the treatment
and diagnosis of haematological and solid organ malignancies; bringing benefit to millions …

CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy.

AE Bras, A Beishuizen, AW Langerak… - British Journal of …, 2018 - search.ebscohost.com
The article discusses a study on paediatric leukemia and lymphoma. Topics include CD38, a
non-lineage-restricted cell surface protein that is strongly expressed on plasma cells (PC) …

How to integrate elotuzumab and daratumumab into therapy for multiple myeloma

CC Hofmeister, S Lonial - Journal of Clinical Oncology, 2016 - ascopubs.org
Purpose Treatment options and outcomes for patients with multiple myeloma have
dramatically improved over the past decade with new agents and drug targets for patients at …

The safety of daratumumab for the treatment of multiple myeloma

MJ Cejalvo, P Ribas, J de la Rubia - Expert Opinion on Drug Safety, 2017 - Taylor & Francis
Introduction: The overall survival of patients with multiple myeloma (MM) has changed
dramatically in the last decade. MM remains an incurable plasma cell disorder but …

Κλινική εμπειρία απο την χρορήγηση του Daratumumab (anti-CD38) στην θεραπεία του πολλαπλού μυελώματος

Ν Γκουγλέρη - repo.lib.duth.gr
Το πολλαπλοφν μυζλωμα αποτελεί κακοικεια των πλαςματοκυττάρων και μζχρι πριν από λίγα
χρόνια οι κεραπείεσ περιοριηόταν ςτουσ αλκυλιοφντεσ παράγοντεσ και τα κορτικοειδι …